L-Norleucine, N-acetyl-L-tryptophyl-6-diazo-5-oxo-, 1-methylethyl ester

Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response[1][2].

[1] Yumi Yokoyama, et al. DRP-104, a novel broad acting glutamine antagonist, induces distinctive immune modulation mechanisms and synergistic efficacy in combination with immune checkpoint blockade. J Immunother Cancer. 2019 Nov 6;7(Suppl 1):282. DOI:10.1186/s40425-019-0763-1

[2] Yumi Yokoyama, et al. DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade in vivo. Cancer Res 2021;81(13_Suppl):Abstract nr 1563.
[3] RANA RAIS. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug[J]. Science Advances, 2022, 8 46. DOI: 10.1126/sciadv.abq5925